MIICRO's Neuroimaging Method Receives Patent Allowance=20

October 6, 1997

------------------------------------------------------------------------
CHICAGO, Oct. 3 /PRNewswire/ via Individual Inc. -- MIICRO, Inc. =
announced today that the U.S. Patent and Trademark Office has issued the =
company a Notice of Allowance on the company's Patent Application, =
"Determining Effects of Psychoactive Compounds on the Brain Using PET."=20

The company's core technology, the OMEI(TM) method, relates a condition =
in the brain to a stimulus effect through analysis of statistical =
metabolic image data. The technology has been previously unavailable to =
the pharmaceutical and biotechnology industries. MIICR0's method =
measures downstream changes in regional glucose metabolism to show how =
drugs alter the brain's activity: the end-effect of the drug-receptor =
interaction and sequentially induced post-synaptic responses.=20

Using MIICRO's method of metabolic imaging, drug developers can =
eliminate the costly guess work that typifies much of the central =
nervous system (CNS) drug development industry. Currently, developers =
spend about $500 million over 15 years to bring a single drug to market. =
However, only 20% of compounds entering human clinical trials will ever =
receive FDA approval. Metabolic neuroimaging will allow developers to =
identify ineffective CNS compounds before wasting time and money. =
Developers will also design more effective and inexpensive Phase II =
trials because they will better determine a drug's effectiveness within =
the quantified dose range.=20

MIICRO's President and CEO, Ciaran Cooper co-founded the company in 1995 =
and raised $1.4 million in private equity capital. Proceeds from the =
private placement have been used to fund marketing and sales activities, =
as well as to further develop the company's core technology. The =
company's research and development plan includes support from government =
sponsored grants (such as SBIR awards), collaborative research with =
pharmaceutical and biotech companies, and its own directed research. The =
company is currently engaged in a second round of financing that will =
enable it to carry out its operations to an anticipated IPO.=20

"We are very pleased to announce the issuance of our first U.S. patent, =
" commented Mr. Cooper. "We are privileged to have received such an =
endorsement of our core technology through this rigorous process."=20

MIICRO, Inc. is a privately held, specialized bioinformatics contract =
research organization that provides neuroimaging services and expertise =
to the pharmaceutical and biotech industries. In addition to =
collaborating with multinational pharmaceutical companies, the company =
has a directed research program aimed at further developing applications =
for the OMEI(TM) method.=20

This press release contains forward-looking statements that invoke risk =
and uncertainties.=20

SOURCE MIICRO, Inc.=20

/CONTACT: Declan Cooper, Vice President of MIICRO, Inc., 312-455-0934, =
[log in to unmask] /Web site: http://www.miicro-inc.com/=20

=A0